These findings highlighted the importance of the TME in promoting cancer progression and suggested that targeted disruption of tumor-stromal interactions, such as those mediated by KCNE4, could represent a promising strategy for the development of novel anti-cancer therapeutics. The gene discussed is KCNE4; the disease is cancer.